PDUFA Bill Moves To Senate Mark-Up, But Without Generic Biologics Language
This article was originally published in The Pink Sheet Daily
April 18 session is planned in the HELP Committee as advocates for follow-on pathway continue to press their case.
You may also be interested in...
In letters sent to legislators, BIO asks Congress to adopt the principles, emphasizing patient health and biotech innovation.
Reps. Waxman and Markey introduce legislation to give FDA stronger post-market enforcement authority, including higher fines than in a Senate version of the bill.
At Senate hearing, co-author of ANDA legislation says that FDA should require clinical trials from sponsors seeking follow-on biologic approval.